One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling ... In terms of achieving the highest alpha, owning the stock for two years may be the shrewdest ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback